Moleculin Biotech, Inc. (MBRX)
NASDAQ: MBRX · Real-Time Price · USD
0.4839
+0.0017 (0.35%)
Oct 7, 2025, 1:42 PM EDT - Market open
Moleculin Biotech Employees
Moleculin Biotech had 17 employees as of December 31, 2024. The number of employees decreased by 1 or -5.56% compared to the previous year.
Employees
17
Change (1Y)
-1
Growth (1Y)
-5.56%
Revenue / Employee
n/a
Profits / Employee
-$1,561,765
Market Cap
23.95M
Employees Chart
Employees History
Date | Employees | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 17 | -1 | -5.56% |
Dec 31, 2023 | 18 | -1 | -5.26% |
Dec 31, 2022 | 19 | 2 | 11.76% |
Dec 31, 2021 | 17 | 2 | 13.33% |
Dec 31, 2020 | 15 | -1 | -6.25% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
Company Name | Employees |
---|---|
UnitedHealth Group | 400,000 |
Johnson & Johnson | 138,100 |
Thermo Fisher Scientific | 125,000 |
Abbott Laboratories | 114,000 |
AstraZeneca | 92,900 |
Novo Nordisk | 77,349 |
Novartis AG | 75,883 |
Merck & Co. | 75,000 |
MBRX News
- 12 days ago - Moleculin Announces Notice of Allowance for Canadian Patent Covering Annamycin - GlobeNewsWire
- 4 weeks ago - Moleculin Accelerates Recruitment in Phase 3 Acute Myeloid Leukemia “MIRACLE” Clinical Trial - GlobeNewsWire
- 4 weeks ago - Moleculin Doses First EU Patient in Phase 3 Pivotal MIRACLE Trial for Treatment of Acute Myeloid Leukemia - GlobeNewsWire
- 5 weeks ago - Moleculin Announces Exercise of Warrants for $6.0 Million Gross Proceeds - GlobeNewsWire
- 5 weeks ago - Moleculin Issues New Positive AML Overall Survival Data: - GlobeNewsWire
- 7 weeks ago - Moleculin to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech - GlobeNewsWire
- 7 weeks ago - Moleculin Reports Second Quarter 2025 Financial Results and Highlights - GlobeNewsWire
- 2 months ago - Moleculin Biotech, Inc. Unveils Promising Preclinical Data of Annamycin in Liver Cancer Treatment - GlobeNewsWire